Search Within

Genitourinary Oncology Service

  1. "Lymphoma"
Formats
  1. Journal Article (7)
  2. Meeting Abstract (6)
  3. Book Section (2)
Groups
  1. Center for Hematologic Malignancies (15)
  2. Department of Medicine (15)
  3. Hematologic Malignancies, Division of (15)
  4. Lymphoma (15)
  5. Solid Tumor Oncology Division (15)
  6. Survivorship Research (8)

More Groups

People
  1. Andrew Zelenetz (4)
  2. Martin Voss (4)
  3. Matthew Matasar (4)
  4. Alison Moskowitz (3)
  5. Carol Portlock (3)
  6. Connie Batlevi (3)

More People

Years
  1. 2025 (2)
  2. 2021 (3)
  3. 2018 (1)
  4. 2017 (1)
  5. 2014 (4)
  6. 2013 (1)

More Years

Publications
  1. Journal of Clinical Oncology (4)
  2. Blood (2)
  3. Cancer (2)
  4. Clinical Cancer Research (1)
  5. Clinical Lymphoma, Myeloma and Leukemia (1)
  6. JCO Clinical Cancer Informatics (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (5)
  2. Wiley Blackwell (3)
  3. American Society of Hematology (2)
  4. Elsevier Inc. (2)
  5. American Association for Cancer Research (1)
  6. Oxford University Press (1)

More Publishers

Results (15)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immuno-oncologyDupilumab for bullous pemphigoid related to immune checkpoint inhibitors: A retrospective case series
    Journal Article

    Nykaza, I.; Moy, A.; Dusza, S. W.; Moskowitz, A.; Iyer, G.; Iqbal, A.; Motzer, R.; Ilson, D. H.; O'Cearbhaill, R. E.; Kazi, R.; more...
    The Oncologist (2025)

    Fulltext@MSK | Save
  • Effect of post-discharge symptom monitoring on hospital readmissions: A randomized trial
    Meeting Abstract

    Daly, R. M.; Mao, J. J.; Cracchiolo, J. R.; Holland, J. C.; Huang, J.; Ebstein, A. M.; Walters, C.; Ackerman, J.; Raj, N. P.; Sanford, R. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Provision of subspecialized expert oncology (SEO) opinions using Navya Cancer Data Model (NCDM), a technology-based platform: Prospective study to facilitate access to care
    Meeting Abstract

    Traina, T. A.; Kantoff, P. W.; Matasar, M. J.; Dunn, L.; Friedman, C. F.; Voss, M. H.; Seidman, A. D.; Cahlon, O.; Zauderer, M. G.; Manship, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Cellular therapy during COVID-19: Lessons learned and preparing for subsequent waves
    Journal Article

    Nawas, M. T.; Shah, G. L.; Feldman, D. R.; Ruiz, J. D.; Robilotti, E. V.; Aslam, A. A.; Dundas, M.; Kamboj, M.; Barker, J. N.; Cho, C.; more...
    Transplantation and Cellular Therapy (2021)

    Fulltext@MSK | Save
  • OncoTree: A cancer classification system for precision oncology
    Journal Article

    Kundra, R.; Zhang, H.; Sheridan, R.; Sirintrapun, S. J.; Wang, A.; Ochoa, A.; Wilson, M.; Gross, B.; Sun, Y.; Madupuri, R.; more...
    JCO Clinical Cancer Informatics (2021)

    Fulltext@MSK | Save
  • Survivorship care
    Book Section

    Tonorezos, E.; Baxi, S. S.; Blinder, V.; Feldman, D. R.; Friedman, D. N.; Matasar, M.; Salz, T.; Shahrokni, A.; Oeffinger, K. C.
    In The American Cancer Society (Eds.) The American Cancer Society's Principles of Oncology: Prevention to Survivorship (2018)

    Fulltext@MSK | Save
  • The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma
    Journal Article

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Clinical and histologic characterization of dermatologic adverse events front the pan-PI3K inhibitor buparlisib (BKM-120)
    Meeting Abstract

    Schindler, K.; Abraham, R.; Shah, P. D.; Chandarlapaty, S.; Paik, P. K.; Bell-Mcguinn, K.; Bajorin, D. F.; Mellinghoff, I. K.; Younes, A.; Gounder, M. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial
    Meeting Abstract

    Scher, H. I.; Fizazi, K.; Lee, C.; Maclean, D.; Tejura, B.; Webb, I. J.; Borgstein, N.; Dreicer, R.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Greater total dose and duration of treatment with bortezomib are associated with higher incidence of chalazion and other ocular side effects
    Meeting Abstract

    Ganesh, K.; Batlevi, C.; Zhang, Z. G.; Hassoun, H.; Lendvai, N.; Landau, H.; Moskowitz, C. H.; Caron, P.; Motzer, R.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save